These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 36711812)

  • 1. Utilizing Electronic Health Records (EHR) and Tumor Panel Sequencing to Demystify Prognosis of Cancer of Unknown Primary (CUP) patients.
    Moon I; LoPiccolo J; Baca SC; Sholl LM; Kehl KL; Hassett MJ; Liu D; Schrag D; Gusev A
    Res Sq; 2023 Jan; ():. PubMed ID: 36711812
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Machine learning for genetics-based classification and treatment response prediction in cancer of unknown primary.
    Moon I; LoPiccolo J; Baca SC; Sholl LM; Kehl KL; Hassett MJ; Liu D; Schrag D; Gusev A
    Nat Med; 2023 Aug; 29(8):2057-2067. PubMed ID: 37550415
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Site-Specific and Targeted Therapy Based on Molecular Profiling by Next-Generation Sequencing for Cancer of Unknown Primary Site: A Nonrandomized Phase 2 Clinical Trial.
    Hayashi H; Takiguchi Y; Minami H; Akiyoshi K; Segawa Y; Ueda H; Iwamoto Y; Kondoh C; Matsumoto K; Takahashi S; Yasui H; Sawa T; Onozawa Y; Chiba Y; Togashi Y; Fujita Y; Sakai K; Tomida S; Nishio K; Nakagawa K
    JAMA Oncol; 2020 Dec; 6(12):1931-1938. PubMed ID: 33057591
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical and molecular characterization of patients with cancer of unknown primary in the modern era.
    Varghese AM; Arora A; Capanu M; Camacho N; Won HH; Zehir A; Gao J; Chakravarty D; Schultz N; Klimstra DS; Ladanyi M; Hyman DM; Solit DB; Berger MF; Saltz LB
    Ann Oncol; 2017 Dec; 28(12):3015-3021. PubMed ID: 29045506
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of molecular profiling in the diagnosis and management of metastatic undifferentiated cancer of unknown primary
    Dermawan JK; Rubin BP
    Semin Diagn Pathol; 2021 Nov; 38(6):193-198. PubMed ID: 33309276
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of Targeted Next-Generation Sequencing for the Management of Patients Diagnosed with a Cancer of Unknown Primary.
    Fusco MJ; Knepper TC; Balliu J; Del Cueto A; Laborde JM; Hooda SM; Brohl AS; Bui MM; Hicks JK
    Oncologist; 2022 Feb; 27(1):e9-e17. PubMed ID: 35305098
    [TBL] [Abstract][Full Text] [Related]  

  • 7. "Metastatic Cancer of Unknown Primary" or "Primary Metastatic Cancer"?
    Kolling S; Ventre F; Geuna E; Milan M; Pisacane A; Boccaccio C; Sapino A; Montemurro F
    Front Oncol; 2019; 9():1546. PubMed ID: 32010631
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Complete genomic characterization in patients with cancer of unknown primary origin in routine diagnostics.
    Schipper LJ; Samsom KG; Snaebjornsson P; Battaglia T; Bosch LJW; Lalezari F; Priestley P; Shale C; van den Broek AJ; Jacobs N; Roepman P; van der Hoeven JJM; Steeghs N; Vollebergh MA; Marchetti S; Cuppen E; Meijer GA; Voest EE; Monkhorst K
    ESMO Open; 2022 Dec; 7(6):100611. PubMed ID: 36463731
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cancer of unknown primary with EGFR mutation successfully treated with targeted therapy directed by clinical next-generation sequencing: a case report.
    Mitani Y; Kanai M; Kou T; Kataoka S; Doi K; Matsubara J; Ohashi S; Matsumoto S; Muto M
    BMC Cancer; 2020 Dec; 20(1):1177. PubMed ID: 33267781
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Quest for Improving Treatment of Cancer of Unknown Primary (CUP) Through Molecularly-Driven Treatments: A Systematic Review.
    Lombardo R; Tosi F; Nocerino A; Bencardino K; Gambi V; Ricotta R; Spina F; Siena S; Sartore-Bianchi A
    Front Oncol; 2020; 10():533. PubMed ID: 32457826
    [No Abstract]   [Full Text] [Related]  

  • 11. AI Helps Untangle Cancer Mysteries.
    Cancer Discov; 2023 Oct; 13(10):2114. PubMed ID: 37638809
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 90-Gene Expression Profiling for Tissue Origin Diagnosis of Cancer of Unknown Primary.
    Zhang Y; Xia L; Ma D; Wu J; Xu X; Xu Y
    Front Oncol; 2021; 11():722808. PubMed ID: 34692498
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A clinical review of the investigation and management of carcinoma of unknown primary in a single cancer network.
    Shaw PH; Adams R; Jordan C; Crosby TD
    Clin Oncol (R Coll Radiol); 2007 Feb; 19(1):87-95. PubMed ID: 17305260
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Does Cancer of Unknown Primary (CUP) Truly Exist as a Distinct Cancer Entity?
    Bochtler T; Krämer A
    Front Oncol; 2019; 9():402. PubMed ID: 31165045
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular gene expression profiling to predict the tissue of origin and direct site-specific therapy in patients with carcinoma of unknown primary site: a prospective trial of the Sarah Cannon research institute.
    Hainsworth JD; Rubin MS; Spigel DR; Boccia RV; Raby S; Quinn R; Greco FA
    J Clin Oncol; 2013 Jan; 31(2):217-23. PubMed ID: 23032625
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A molecular approach integrating genomic and DNA methylation profiling for tissue of origin identification in lung-specific cancer of unknown primary.
    Chen K; Zhang F; Yu X; Huang Z; Gong L; Xu Y; Li H; Yu S; Fan Y
    J Transl Med; 2022 Apr; 20(1):158. PubMed ID: 35382836
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Case Report: Molecular Profiling Assists in the Diagnosis and Treatment of Cancer of Unknown Primary.
    Yu B; Wang Q; Liu X; Hu S; Zhou L; Xu Q; Sun Y; Hu X; Luo Z; Zhang X
    Front Oncol; 2022; 12():723140. PubMed ID: 35433426
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune and genomic biomarkers of immunotherapy response in cancer of unknown primary.
    Posner A; Sivakumaran T; Pattison A; Etemadmoghadam D; Thio N; Wood C; Fisher K; Webb S; DeFazio A; Wilcken N; Gao B; Karapetis CS; Singh M; Collins IM; Richardson G; Steer C; Warren M; Karanth N; Fellowes A; Fox SB; Hicks RJ; Schofield P; Bowtell D; Prall OWJ; Tothill RW; Mileshkin L
    J Immunother Cancer; 2023 Jan; 11(1):. PubMed ID: 36720497
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Carcinoma of Unknown Primary Site (CUP) With Metastatic Renal-Cell Carcinoma (mRCC) Histologic and Immunohistochemical Characteristics (CUP-mRCC): Results From Consecutive Patients Treated With Targeted Therapy and Review of Literature.
    Overby A; Duval L; Ladekarl M; Laursen BE; Donskov F
    Clin Genitourin Cancer; 2019 Feb; 17(1):e32-e37. PubMed ID: 30268423
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Integrated clinicomolecular characterization identifies RAS activation and CDKN2A deletion as independent adverse prognostic factors in cancer of unknown primary.
    Bochtler T; Reiling A; Endris V; Hielscher T; Volckmar AL; Neumann O; Kirchner M; Budczies J; Heukamp LC; Leichsenring J; Allgäuer M; Kazdal D; Löffler H; Weichert W; Schirmacher P; Stenzinger A; Krämer A
    Int J Cancer; 2020 Jun; 146(11):3053-3064. PubMed ID: 31970771
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.